RE:RE:RE:RE:RE:RE:Today’s News Intersting C.C & equally interesting responses on here.
ill start & end my thoughts, on the CC
First, & not discussed. Dr. Matt is still off sick.
Regarding the CC content.
There were some very specific questions from 3 separate analysts.
Will be interesting to see their responses going forward.
upgrade,downgrade or stay the same?
My guess is staying the same. or improved.
explanations:
This was the first time, Onc has ever discussed sales $$ potential of Pela.
That being $2.5 billion/ year for MBc only.
No talks about the $$ value of Panc cancer, or then other G.I. Subsets they are working on.
The B.D. Guy clearly updated & mentioned by name pfizer & Roche, as well as widening the scope to other companies & countries.
He also, gave some important insight to the process. They had been in talks with ," pharma colaborators" , they wanted to see the final data.
Those following my writings. That is exactly what I said a few days ago.
With the final MBc data in- place & sales forecasts they now have a much clearer & positive product to offer.
My point, the negotiators are legally bound with getting the best $$ value for shareholders moving forward.
A clear very positive set of data, alongside sales estimates of $2.5 billion/ year, ...is a wonderful basket to negotiate from.
Years ago, it was discussed they wanted to create as broad an interst as possible, hoping to create a competitive negotiating position.
Todays discussion naming Europe, Asia as well as existing Pfizer & Roche " and others", reiterates that stratagy.
During the CC nothing was discussed outside of the top two; MBc & pancreatic cancer.
Great exaplanation on the history. Including the $5 million grant.
regarding those who can't wait to trash Onc and/ or those of us who have shares.
Its sad to see reported " mumble jumble" , Just because you grade school education limits your comprehension, does not make people's comments " mumble jumble" , Sadly your FUD, is only emberassing to read.
Those attacking me directly, as I have not yet chimed in.
Pre- concluding I'm worried , etc.
ill answer that directly. I'm not worried at all. Very busy.
I did listen to the call. Then had my 2 hr am walk.
Some important things to deal with. Now a bit of rest time.
fYI, I followed Onc for many years. Cancer? Everyone on my moms side, staring with my grandparents died of cancer.
such numbers that a few cousins of mine, were part of a geniology study , out of a university in Saskatchewan.
My point, I want to see Pela approved & help cancer patients.
Reading Onc founding documents, that is now & always has been oncs goal.
Closing on the CC, There was nothing new updated clinically. Lost of " process" discussions.
That being accelerated approval,various trial start dates, enrolment opportunities etc.
Best statement was regarding the Panc cancer enrolment.
( sadley) panc cancer is not rare & extreamly deadly. ...meaning lots of patients & they have a very wide support network. Enrocan be rapid.
My opinions on closing.
Thanks again , notable for your resurch. BTW, the question " why post about other pharma companies".
One needs to think a bit.... obvious comparables to Pela/ Onc abilities & market cap.
vs
pharma X, and its market cap.
Using that comparable alone ( which one of the analyst does as well), Onc is worth a couple of $ billion, being very conservative.
Todays call?
Nothing specific clinically new, lots of background on going forward.
Nothing negative.
Great descriptions of the process going forward.
My opinion, a complete buyout can & will happen.
A partnership is not a bad thing. However a complete buyout would be in best interest of everyone.
As the intern ceo said in closing.
hope everyone has a great day.